CompletedPhase 2NCT05001269
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Studying Primary hyperoxaluria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Principal Investigator
- Sarb Shergill, PhDDicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Intervention
- nedosiran(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 11 years · All sexes
- Timeline
- 2022 – 2025
Study locations (13)
- Clinical Research Site, Rochester, Minnesota, United States
- Clinical Research Site, Hamilton, Ontario, Canada
- Clinical Trial Site, Bonn, Germany
- Clinical Research Site, Heidelberg, Germany
- Clinical Trial Site, Roma, Italy
- Clinical Research Site, Fukuoka, Japan
- Clinical Research Site, Nagoya, Japan
- Clinical Research Site, Beirut, Lebanon
- Clinical Research Site, Bialystok, Poland
- Clinical Research Site, Barcelona, Spain
- Clinical Research Site, Yenimahalle, Ankara, Turkey (Türkiye)
- Clinical Trial Site, Dubai, United Arab Emirates
- Clinical Trial Site, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05001269 on ClinicalTrials.govOther trials for Primary hyperoxaluria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06839235Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)Arbor Biotechnologies
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06892301Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Guangzhou Women and Children's Medical Center
- RECRUITINGEARLY PHASE1NCT06511349Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RenJi Hospital
- RECRUITINGNCT06225882Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.Hospices Civils de Lyon
- ACTIVE NOT RECRUITINGNCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Alnylam Pharmaceuticals
- RECRUITINGPHASE2NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDDicerna Pharmaceuticals, Inc., a Novo Nordisk company